257 related articles for article (PubMed ID: 20415623)
1. Topical cyclosporine 0.05% for the prevention of dry eye disease progression.
Rao SN
J Ocul Pharmacol Ther; 2010 Apr; 26(2):157-64. PubMed ID: 20415623
[TBL] [Abstract][Full Text] [Related]
2. Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal.
Rao SN
J Ocul Pharmacol Ther; 2011 Dec; 27(6):603-9. PubMed ID: 21999340
[TBL] [Abstract][Full Text] [Related]
3. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
[TBL] [Abstract][Full Text] [Related]
4. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
Demiryay E; Yaylali V; Cetin EN; Yildirim C
Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
Salib GM; McDonald MB; Smolek M
J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
[TBL] [Abstract][Full Text] [Related]
6. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of topical cyclosporine for the treatment of dry eye disease.
Perry HD; Solomon R; Donnenfeld ED; Perry AR; Wittpenn JR; Greenman HE; Savage HE
Arch Ophthalmol; 2008 Aug; 126(8):1046-50. PubMed ID: 18695097
[TBL] [Abstract][Full Text] [Related]
8. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
Su MY; Perry HD; Barsam A; Perry AR; Donnenfeld ED; Wittpenn JR; D'Aversa G
Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye.
Guzey M; Karaman SK; Satici A; Ozardali I; Sezer S; Bozkurt O
Clin Exp Ophthalmol; 2009 Aug; 37(6):541-9. PubMed ID: 19702702
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye.
Sall KN; Cohen SM; Christensen MT; Stein JM
Eye Contact Lens; 2006 Jan; 32(1):21-6. PubMed ID: 16415689
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.
Willen CM; McGwin G; Liu B; Owsley C; Rosenstiel C
Eye Contact Lens; 2008 Jan; 34(1):43-5. PubMed ID: 18180683
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease.
Rao SN; Rao RD
Cornea; 2006 Jul; 25(6):674-8. PubMed ID: 17077659
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye.
Byun YJ; Kim TI; Kwon SM; Seo KY; Kim SW; Kim EK; Park WC
Cornea; 2012 May; 31(5):509-13. PubMed ID: 19730097
[TBL] [Abstract][Full Text] [Related]
15. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction.
Prabhasawat P; Tesavibul N; Mahawong W
Cornea; 2012 Dec; 31(12):1386-93. PubMed ID: 23135530
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of an isotonic tear in combination with topical cyclosporine for the treatment of ocular surface disease.
Hardten DR; Brown MJ; Pham-Vang S
Curr Med Res Opin; 2007 Sep; 23(9):2083-91. PubMed ID: 17822610
[TBL] [Abstract][Full Text] [Related]
17. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.
Wilson SE; Perry HD
Ophthalmology; 2007 Jan; 114(1):76-9. PubMed ID: 17070588
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine 0.05% to improve visual outcomes after multifocal intraocular lens implantation.
Donnenfeld ED; Solomon R; Roberts CW; Wittpenn JR; McDonald MB; Perry HD
J Cataract Refract Surg; 2010 Jul; 36(7):1095-100. PubMed ID: 20610085
[TBL] [Abstract][Full Text] [Related]
19. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
Barber LD; Pflugfelder SC; Tauber J; Foulks GN
Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
[TBL] [Abstract][Full Text] [Related]
20. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome.
Kim EC; Choi JS; Joo CK
Am J Ophthalmol; 2009 Feb; 147(2):206-213.e3. PubMed ID: 18848318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]